Fineline Cube

Follow:
14771 Articles
Innovent Biologics' IBI363 Receives FDA Fast-Track Designation for sqNSCLC
CompanyDrug

Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC

Tianyi Medical Acquires Bellco's CRRT Filter Business for EUR11.99m
CompanyDeals

Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m

Konruns Pharmaceutical's KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents
CompanyDrug

Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval
CompanyDrug

Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing's Departure on BCHT Biotechnology
Company

Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing
Company

Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing

AI Transformation in Chinese Medicine: DeepSeek Drives Market Uptick
CompanyDigital

Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by Proxima Ventures
Company

LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures

New Guidelines for Advanced Gastric Cancer Drug Development Released in China
Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Bristol Myers Squibb's Opdualag Fails to Meet Primary Endpoint in Melanoma Study
CompanyDrug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Hengrui's Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
CompanyDrug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials
Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials